Invo BioScience (INVO)
(Delayed Data from NSDQ)
$0.84 USD
+0.02 (2.18%)
Updated Aug 23, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
INVO 0.84 +0.02(2.18%)
Will INVO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for INVO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for INVO
MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Misses Revenue Estimates
Clovis Oncology (CLVS) Reports Q3 Loss, Lags Revenue Estimates
INVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regenxbio (RGNX) Reports Q3 Loss, Lags Revenue Estimates
Invo BioScience Inc. (INVO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Invo BioScience Inc. (INVO) Upgraded to Buy: Here's What You Should Know
Other News for INVO
INVO BioScience GAAP EPS of -$0.62, revenue of $1.84M
INVO Stock Earnings: INVO Bioscience Reported Results for Q2 2024
INVO Reports Record Second Quarter 2024 Financial Results with 481% Revenue Growth and a $1.1 Million Improvement to Adjusted EBITDA
INVO Bioscience reports Q2 EPS (62c) vs. ($3.06) last year
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session